



# Center for Harm Reduction Services (CHRS)

**Janelle Hodgson, MPH, Epidemiologist**

**Jasmine Lopes, MPH, Epidemiologist**

March 27, 2024


# **SSP Data Updates**

---


**SFY24-Q2 Program Data (October 1, 2023 -  
December 31, 2023)**

# New Participants Registered & Total Participants Served

Number of New Participants Registered Q2-FY23 and Q2-FY24




Total Participants Served Q2-FY23 and Q2-FY24




# Syringes Distributed/Collected

Number of Syringes Collected Q2-FY23 and Q2-FY24




Number of Syringes Distributed Q2-FY23 and Q2-FY24



# Direct Services

## Direct services



# Wound Care


---

A total of **10,334 wound care direct services** were provided in FY24-Q2

- Hands on wound care: 384
- Wound care kit supplies: 9,550

# Referrals/Linkage to Care


## Referrals/Linkage to Care Services



---

# Rapid Analysis of Drugs (RAD) Update

# Participating Syringe Service Programs



Source: Rapid Analysis of Drugs (RAD), Reporting Period 10/1/2021 to 3/19/2024

# Samples Collected

---

- Sample Collection began in October 2021 and is continuing
- As of 3/19/2024, 2,588 samples have been tested.
- 17 of the 25 SSPs in Maryland collect samples.
  - Covering 12 jurisdictions

New [RAD Report](#) Available!

- Focuses on xylazine in Maryland from October 2021 - October 2023.




# RAD Data Disclaimers

---

- Convenience Sampling -
  - RAD is a completely voluntary program that Maryland SSP participants can choose to engage in
  - Not all MD jurisdictions have an SSP that participate in RAD
- No personally identifiable data is collected, therefore we do not know how many participants are accounted for in the sample size


RAD gives us some indication of the near real time drug market in Maryland, but it should not be considered as fully representative.

# RAD Sampling by Jurisdiction



Source: Rapid Analysis of Drugs (RAD), Reporting Period 10/1/2021 to 3/19/2024


# RAD Sampling by Jurisdiction, Oct 2021 - March 2024



Source: Rapid Analysis of Drugs (RAD), Reporting Period 10/1/2021 to 3/19/2024

**Note:** Data is preliminary and subject to change.


# RAD Compounds, Oct 2021 - March 2024



Source: Rapid Analysis of Drugs (RAD), Reporting Period 10/1/2021 to 3/19/2024

# Samples Containing Cocaine


- 38.4% of samples tested contained cocaine.
- In CY24 Q1 (January - March) there were a total of 52 samples that contained cocaine.
- 20.6% decrease from the previous quarter (CY23 Q4)
- 15.1% decrease in samples containing cocaine from same time last year (CY23 Q1)



**Note:** Data is preliminary and subject to change.

# Samples Containing Xylazine


- 32.6% of samples tested contained xylazine.
- In CY24 Q1 (January - March) there were a total of 84 samples that contained xylazine.
- 27.9% increase from the previous quarter (CY23 Q4)
- 19.5% increase in samples containing xylazine from same time last year (CY23 Q1)



**Note:** Data is preliminary and subject to change.

# Samples Containing Fentanyl & Fentanyl Analogs


- 45.8% of samples tested contained fentanyl.
- In CY24 Q1 (January - March) there were a total of 100 samples that contained fentanyl.
- 31.7% increase from the previous quarter (CY23 Q4)
- 12.3% increase in samples containing fentanyl from same time last year (CY23 Q1)



**Note:** Data is preliminary and subject to change.

# Samples Containing Other Opioids

- 0.8% of samples tested contained other opioids.
- In CY24 Q1 (January - March) there were no samples that contained other opioids.




**Note:** Data is preliminary and subject to change.

Source: Rapid Analysis of Drugs (RAD), Reporting Period 10/1/2021 to 3/19/2024

# Samples Containing Amphetamines


- 6.3% of samples tested contained amphetamines.
- In CY24 Q1 (January - March) there were a total of 14 samples that contained Amphetamines.
- 6% decrease from the previous quarter (CY23 Q4)
- 2.1% increase in samples containing amphetamines from same time last year (CY23 Q1)



**Note:** Data is preliminary and subject to change.

# Samples Containing Heroin & Related Compounds

- 0.9% of samples tested contained heroin.
- In CY24 Q1 (January - March) there were a total of 1 sample that contained heroin.
- 0.3% decrease from the previous quarter (CY23 Q4)
- 1.1% decrease in samples containing heroin from same time last year (CY23 Q1)



**Note:** Data is preliminary and subject to change.

Source: Rapid Analysis of Drugs (RAD), Reporting Period 10/1/2021 to 3/19/2024

# THANK YOU!

---

Questions regarding Syringe Service Programs please email:  
[mdh.syringeservices@maryland.gov](mailto:mdh.syringeservices@maryland.gov)

## Contact Us:

Janelle Hodgson

[janelle.hodgson@maryland.gov](mailto:janelle.hodgson@maryland.gov)

Jasmine Lopes

[Jasmine.lopes@maryland.gov](mailto:Jasmine.lopes@maryland.gov)

Maggie Rybak

[Margaret.rybak@maryland.gov](mailto:Margaret.rybak@maryland.gov)